Business

Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025

GOLETA, Calif., January 12, 2026--Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

articleInogen, IncJanuary 12, 20264/company/inogen-inc/news/inogen-announces-preliminary-revenue-results-133000591
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025

About this update from Inogen, Inc

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1296,"height":446,"url":"https://media.zenfs.com/en/business-wire.com/210a8947dac3e859a8acc5a74a69d10f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vFdIb93f7R9l_Uvn7JRBwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/210a8947dac3e859a8acc5a74a69d10f","width":960,"height":330},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4djt.blY4ik8XwoKYxgoPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/210a8947dac3e859a8acc5a74a69d10f","width":1200,"height":413}},"lazy":false},{"type":"text","content":"Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 ","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"GOLETA, Calif., January 12, 2026--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025.","length":287,"tagName":"p"},{"type":"text","content":"The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%.","length":331,"tagName":"p"},{"type":"text","content":"For the full year 2025, the Company expects to achieve positive Adjusted EBITDA, reflecting its continued commitment to financial discipline and effective cost management.","length":171,"tagName":"p"},{"type":"text","content":""While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shift in the timing of a few large customer orders into the first half of 2026. Although this delay relative to expectations is disappointing, our full year results continued to make meaningful progress in executing our business turnaround," said Kevin Smith, President and Chief Executive Officer. "Highlights for the full year include positive revenue growth, advanci...

More updates from Inogen, Inc

Inogen, Inc.respiratory careInogen Investor RelationsInogenThe CompanyForward-Looking Statementsrespiratory therapy